Evidence map›Paper›PMID 41083549›Full record

ArticleScientific reports2025

Predicting one-year overall survival in patients with AITL using machine learning algorithms: a multicenter study.

Xufei Huang, Chunlan Zhang, Kejia Liu, Fatian Wu, TianYu Feng, Caigang Xu

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xufei Huang *Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fujian, China.
Chunlan Zhang *Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Kejia LiuDHC Mediway Technology Co., Ltd, Beijing, China.
Fatian WuDHC Mediway Technology Co., Ltd, Beijing, China.
TianYu FengDHC Mediway Technology Co., Ltd, Beijing, China.
Caigang XuDepartment of Hematology, West China Hospital, Sichuan University, Chengdu, China. xucaigang@wchscu.cn.

Funding

Fujian Provincial Clinical Research Center for Hematological Malignancies 2020Y2006National Natural Science Foundation of China 82000210Sichuan science and technology department for key research and development projects 2019YFS0027
6 · The paper itself

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a life-threatening hematological malignancy. For patients with poor prognosis, especially those with expected survival less than 1 year, the benefits from traditional regimens are extremely limited. Therefore, we aimed to develop an interpretable machine learning (ML)-based model to predict the 1-year overall survival (OS) of AITL patients. A total of 223 patients with AITL treated in 4 centers in China were included. Five ML algorithms were built to predict 1-year outcome based on 16 baseline characteristics. Recursive feature elimination (RFE) method was used to filter for the most important features. The ML models were interpreted and the relevance of the selected features was determined using the Shapley additive explanations (SHAP) method and the local interpretable model-agnostic explanation (LIME) algorithm. Catboost model presented to be the best predictive model (AUC = 0.8277). After RFE screening, 8 variables demonstrated the best performance (AUC = 0.8125). This study demonstrated that the Catboost model with 8 variables could effectively predict the 1-year overall survival of AITL patients.

Indexed as

Lymphoma, T-CellMachine LearningAdultAgedAlgorithmsChinaFemaleHumansMaleMiddle AgedPrognosisAngioimmunoblastic t-cell lymphomaMachine learningMulticenter studyOverall survivalPrognosis

Identifiers

PMID41083549
PMCPMC12518878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.